Although some nonspecific inhibitors block the function of the SETDB1 protein, there is no specific agent effective yet, so the study of the role of SETDB1 and its molecular interactions in various cancers can help improve the therapeutic targeting of SETDB1 in the clinic (Rodriguez-Paredes et al., 2014). The gene discussed is SETDB1; the disease is cancer.